Comparative Pharmacology
Head-to-head clinical analysis: ORTHO EVRA versus ORTHO NOVUM 10 11 21.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ORTHO EVRA versus ORTHO NOVUM 10 11 21.
ORTHO EVRA vs ORTHO-NOVUM 10/11-21
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination hormonal contraceptive containing ethinyl estradiol and norelgestromin. Ethinyl estradiol suppresses gonadotropin (FSH and LH) release, preventing ovulation. Norelgestromin is a progestin that also inhibits ovulation and induces changes in cervical mucus and endometrium to impede sperm penetration and implantation.
Combination oral contraceptive consisting of norethindrone (progestin) and ethinyl estradiol (estrogen). Prevents ovulation primarily by suppressing gonadotropin release, including FSH and LH. Also increases cervical mucus viscosity, impeding sperm penetration, and alters endometrial structure, reducing implantation likelihood.
Transdermal: Apply one patch (releases 150 mcg norelgestromin and 20 mcg ethinyl estradiol per 24 hours) weekly for 3 weeks, followed by 1 patch-free week. Apply to clean, dry, intact skin on lower abdomen, buttock, upper arm, or upper torso (excluding breasts).
One tablet (10 mg norethindrone/0.035 mg ethinyl estradiol) orally once daily for 21 days, followed by 7 placebo days. Start on first Sunday after menstrual period begins or on day 1 of cycle.
None Documented
None Documented
Norelgestromin: ~28 hours (range 21-36) allowing weekly dosing; Ethinyl estradiol: ~17 hours (range 13-21)
Norethindrone: 7-8 hours (terminal); Ethinyl estradiol: 10-20 hours (terminal). Clinically, steady state reached within 5-7 days.
Renal: ~50% (as glucuronide conjugates of norelgestromin and ethinyl estradiol); Fecal: ~35% (as metabolites); Biliary: minor
Renal: ~50% (metabolites as glucuronide and sulfate conjugates); Fecal: ~30% (via bile); Urinary unchanged: <1%.
Category C
Category C
Hormonal Contraceptive
Hormonal Contraceptive